News
Nice article in C2W (in Dutch) on Venture Challenge Winner AmbAgon
Drugging the undruggable. Esther Thole interviews Venture Challenge winner AmbAgon's founders Luc Brunsveld en Christian Ottmann for C2W.
Sirius Medical proudly announces first international implant
Sirius Medical, a start-up company developing Sirius Pintuition as an affordable, non-radioactive, point source localization technology that enables accurate surgical guidance in oncology is proud to announce the first international implants with the Sirius
Sirius Medical announces FDA clearance of Sirius Pintuition for Breast Cancer Surgery
Sirius Medical announces FDA clearance of Sirius Pintuition for Breast Cancer Surgery. This clearance paves the way for Sirius to launch its Pintuition System in the United States.
Scientific paper by NutriLeads shows that its plant-based RG-I food ingredients support immune function and modulate the microbiota
First scientific data showing immune supportive properties of plant-based RG-I derived from bell pepper and carrot. Study published in the “Nutrition, Immunity and Viral infection” special issue of the peer-reviewed jou
Paul Janssen Futurelab IP course starts April 19th
The J&J/Janssen Covid-19 vaccine that was recently approved by the FDA and EMA is produced using cell line PER.C6 that was originally developed and patented for a quite different application (i.e. gene therapy).
TargED Biopharmaceuticals and Good Biomarker Sciences receive MIT R&D collaboration grant
We are very pleased to announce that Economic Board Utrecht has granted €213.000 to support a 2-year joint R&D program between TargED Biopharmaceuticals and Good Biomarker Sciences.
UFO Biosciences launches its cell subtyping services
UFO Biosciences is happy to announce the launch of its cell subtyping services. UFO Biosciences offers a unique solution to identify rare cell subtypes in a heterogeneous sample population to drive dedicated R&D.
Levels Diagnostics awarded the MIT R&D grant
Levels Diagnostics was awarded the MIT R&D grant by the Provide of South Holland. Together with Omnigen and SG papertronics the consortium will develop a test that can quickly identify early signs of liver damage in patients.
Cristal Therapeutics and Intravacc announce strategic collaboration to advance novel vaccine platforms
Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, to
TargED awarded NWO Take-Off Phase II grant for the development of Microlyse - a next-generation thrombolytic clot-busting drug
We are very pleased to announce that The Netherlands Organization for Scientific Research (NWO) has granted the Take-Off Phase II loan (€250.000) for the further development of our lead compound, Microlyse.